



Main shareholders signs lock-up agreements for 12 months

In connection with the announcement that the Board of Directors of Scandion Oncology A/S (“Scandion Oncology”) has proposed to an Extraordinary General Meeting to conduct an issue of units, main shareholders, Board of Directors and management of Scandion Oncology have signed and prolonged so-called lock-up agreements, which means that they commit to retain 90 percent of their holdings in the company over the upcoming 12 months calculated from June 2019. In total, the lock-up agreements correspond to 53 percent of the share of votes and capital in Scandion Oncology. The following parties have entered into lock-up agreements:

Saniona AB	3,473,577
Jan Stenvang*	1,481,516
Nils Brünner**	1,136,045
Jørgen Bardenfleth***	130,030
Carl Borrebaeck****	79,654
Carit Jacques Andersen*****	55,505
Peter Michael Vestlev*****	20,000
Total	6,326,327 shares

* CSO, Jan Stenvang.

** CEO, Nils Brünner, private and through the company TIMPCO NB ApS.

*** Chairman of the Board Jørgen Bardenfleth, private and through the company Lioneagle ApS.

**** Member of the Board Carl Borrebaeck, through the company CB Ocean Capital AB.

***** CFO, Carit Jacques Andersen, through the company Decisionconsult Holding ApS.

***** CMO, Peter Michael Vestlev.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 3rd, 2019.

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now ready to initiate clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.